Krystal Biotech (NASDAQ:KRYS) Trading 7.5% Higher - What's Next?

Key Points

• Krystal Biotech's share price rose by 7.5% to $154.40, with trading volume increasing significantly to 446,902 shares compared to the average of 327,973 shares.
• HC Wainwright set a $240.00 price target with a "buy" rating on Krystal Biotech, while other analysts provided mixed targets ranging from $192.00 to $216.00.
• The company reported Q2 earnings of $1.29 EPS, exceeding analyst expectations, with revenue of $96.04 million, indicating strong financial performance.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) shares were up 7.5% during mid-day trading on Monday . The stock traded as high as $153.99 and last traded at $154.40. Approximately 446,902 shares traded hands during trading, an increase of 36% from the average daily volume of 327,973 shares. The stock had previously closed at $143.68.

Analysts Set New Price Targets

Several analysts recently issued reports on KRYS shares. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Bank of America reduced their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Chardan Capital reduced their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Finally, Citigroup reaffirmed a "neutral" rating and issued a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $209.00.

Krystal Biotech Trading Up 1.8%

The stock has a market cap of $4.73 billion, a P/E ratio of 33.25 and a beta of 0.66. The company has a 50-day moving average price of $147.98 and a two-hundred day moving average price of $152.14.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company's stock valued at $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. boosted its holdings in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock valued at $126,870,000 after acquiring an additional 481,200 shares during the period. Braidwell LP boosted its holdings in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company's stock valued at $100,045,000 after acquiring an additional 327,067 shares during the period. Geode Capital Management LLC boosted its holdings in Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company's stock valued at $85,174,000 after acquiring an additional 7,194 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after acquiring an additional 365,304 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).